3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
19
Phase 2
9
Phase 1/2
3
Phase NA
2
Phase EARLY_PHASE1
1
Phase 4
1
Phase 3
1
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
22
Thoracic
4
Head & Neck
4
Gastrointestinal
4
Other hematologic neoplasm
3
Gynecologic
3
Breast
3
Myeloid
2
Lymphoid
2
Genitourinary
2
CNS
2
Sarcoma
1
Plasma cell
1
Endocrine
1
Conditions
Neuroendocrine Tumors
7
Thyroid Carcinoma, Anaplastic
3
Thyroid Cancer, Papillary
3
Neoplasms
3
Multiple Endocrine Neoplasia Type 1
3
Thyroid Neoplasms
2
Somatostatinoma
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Laryngeal Neoplasms
2
Hematologic Neoplasms
2
Glioma
2
Gastroenteropancreatic Neuroendocrine Tumors
2
Erdheim-Chester Disease
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Adrenal Gland Neoplasms
2
Adenoma, Islet Cell
2
Vipoma
1
Thyroid cancer, Hurthle cell
1
Pituitary Neoplasms
1
Pheochromocytoma
1
Parathyroid Neoplasms
1
Paraganglioma
1
Muscle Weakness
1
Motor Activity
1
Melanoma
1
Interventions
cobimetinib
1
Vemurafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Melanoma
×
Endocrine
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled